ESMO-话题@MedSci

#ESMO#

214篇内容 | 5050人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1280935, encodeId=3be21280935bd, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著, objectType=article, longId=85001, objectId=ab7e85001cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab7e85001cf, replyNumber=0, likeNumber=71, createdTime=2016-12-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab7e85001cf, moduleTitle=ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab7e85001cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280934, encodeId=2ef212809349b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者, objectType=article, longId=80187, objectId=cbf48018e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf48018e22, replyNumber=0, likeNumber=77, createdTime=2016-10-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf48018e22, moduleTitle=ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf48018e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280933, encodeId=1ba812809338b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016ESMO临床诊疗指南——BRCA突变携带者以及其他乳腺/卵巢遗传性癌症综合征的预防和筛查发布, objectType=article, longId=80002, objectId=6d9a8000242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d9a8000242, replyNumber=0, likeNumber=23, createdTime=2016-10-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d9a8000242, moduleTitle=2016ESMO临床诊疗指南——BRCA突变携带者以及其他乳腺/卵巢遗传性癌症综合征的预防和筛查发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d9a8000242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280932, encodeId=80c612809323f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2015ESMO恶性淋巴瘤共识会议建议——成熟的B细胞淋巴瘤和慢性淋巴细胞白血病的预测工具发布, objectType=article, longId=79904, objectId=d18ae9904b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d18ae9904b4, replyNumber=0, likeNumber=27, createdTime=2016-10-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d18ae9904b4, moduleTitle=2015ESMO恶性淋巴瘤共识会议建议——成熟的B细胞淋巴瘤和慢性淋巴细胞白血病的预测工具发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d18ae9904b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280931, encodeId=257b128093175, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, objectType=article, longId=79864, objectId=5769e986481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769e986481, replyNumber=0, likeNumber=39, createdTime=2016-10-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769e986481, moduleTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769e986481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280930, encodeId=2b17128093067, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, objectType=article, longId=79863, objectId=3fa9e98630a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa9e98630a, replyNumber=0, likeNumber=69, createdTime=2016-10-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa9e98630a, moduleTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa9e98630a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280929, encodeId=62521280929e3, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：nivolumab辅助治疗可切除的非小细胞肺癌, objectType=article, longId=79650, objectId=927ce96505f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=927ce96505f, replyNumber=0, likeNumber=27, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=927ce96505f, moduleTitle=ESMO 2016：nivolumab辅助治疗可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=927ce96505f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280928, encodeId=ba6512809289e, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：新辅助放化疗可延长局部晚期食管鳞状细胞癌患者的生存期, objectType=article, longId=79647, objectId=cd0be96471b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd0be96471b, replyNumber=0, likeNumber=26, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd0be96471b, moduleTitle=ESMO 2016：新辅助放化疗可延长局部晚期食管鳞状细胞癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd0be96471b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280927, encodeId=4f3d128092e95, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：ANG1005可通过血脑屏障，治疗脑转移瘤, objectType=article, longId=79644, objectId=7474e9644c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7474e9644c6, replyNumber=0, likeNumber=58, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7474e9644c6, moduleTitle=ESMO 2016：ANG1005可通过血脑屏障，治疗脑转移瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7474e9644c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280926, encodeId=6b601280926f8, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, objectType=article, longId=79630, objectId=1d17e9630e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d17e9630e6, replyNumber=0, likeNumber=29, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d17e9630e6, moduleTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d17e9630e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280925, encodeId=2e1f1280925f3, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：伊匹单抗治疗黑色素瘤，效果如何？（EORTC 18071试验）, objectType=article, longId=79629, objectId=9f94e9629d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f94e9629d0, replyNumber=0, likeNumber=53, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f94e9629d0, moduleTitle=ESMO 2016：伊匹单抗治疗黑色素瘤，效果如何？（EORTC 18071试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f94e9629d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280924, encodeId=9a7e128092417, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：Alisertib治疗神经内分泌前列腺癌, objectType=article, longId=79627, objectId=1b09e962777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b09e962777, replyNumber=0, likeNumber=52, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b09e962777, moduleTitle=ESMO 2016：Alisertib治疗神经内分泌前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b09e962777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280923, encodeId=3cc1128092388, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, objectType=article, longId=79625, objectId=03fde96257d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fde96257d, replyNumber=0, likeNumber=30, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fde96257d, moduleTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fde96257d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280922, encodeId=09b0128092218, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, objectType=article, longId=79623, objectId=aa97e962349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa97e962349, replyNumber=0, likeNumber=74, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa97e962349, moduleTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa97e962349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280921, encodeId=f164128092185, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）, objectType=article, longId=79621, objectId=d717e96216e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d717e96216e, replyNumber=0, likeNumber=64, createdTime=2016-10-11, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d717e96216e, moduleTitle=ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d717e96216e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280920, encodeId=54e512809208c, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016ESMO临床诊疗指南——胃癌的诊断、治疗与随访发布, objectType=article, longId=79096, objectId=396fe909605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=396fe909605, replyNumber=0, likeNumber=26, createdTime=2016-10-02, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=396fe909605, moduleTitle=2016ESMO临床诊疗指南——胃癌的诊断、治疗与随访发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=396fe909605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280919, encodeId=7f7a128091948, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016ESMO临床诊疗指南——胆管癌的诊断、治疗与随访发布, objectType=article, longId=78935, objectId=642ae893509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=642ae893509, replyNumber=0, likeNumber=31, createdTime=2016-09-30, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=642ae893509, moduleTitle=2016ESMO临床诊疗指南——胆管癌的诊断、治疗与随访发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=642ae893509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280918, encodeId=6ba9128091832, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布, objectType=article, longId=78694, objectId=ac50e8694d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac50e8694d5, replyNumber=0, likeNumber=24, createdTime=2016-09-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac50e8694d5, moduleTitle=2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac50e8694d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280917, encodeId=5713128091e34, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016MASCC/ESMO指南——放化疗相关性恶心呕吐以及晚期肿瘤患者恶心呕吐的预防发布, objectType=article, longId=78691, objectId=2fcce8691d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcce8691d2, replyNumber=0, likeNumber=40, createdTime=2016-09-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcce8691d2, moduleTitle=2016MASCC/ESMO指南——放化疗相关性恶心呕吐以及晚期肿瘤患者恶心呕吐的预防发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcce8691d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280916, encodeId=122f128091629, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2016ESMO临床实践指南——发热性中性粒细胞减少的管理发布, objectType=article, longId=78613, objectId=f8dbe861327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8dbe861327, replyNumber=0, likeNumber=31, createdTime=2016-09-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8dbe861327, moduleTitle=2016ESMO临床实践指南——发热性中性粒细胞减少的管理发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8dbe861327)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著

2016-12-23

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：Tucatinib可有效治疗乳腺癌皮肤转移患者

2016-10-18

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

2016ESMO临床诊疗指南——BRCA突变携带者以及其他乳腺/卵巢遗传性癌症综合征的预防和筛查发布

2016-10-15

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

2015ESMO恶性淋巴瘤共识会议建议——成熟的B细胞淋巴瘤和慢性淋巴细胞白血病的预测工具发布

2016-10-14

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS

2016-10-13

hb2008ye (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS

2016-10-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：nivolumab辅助治疗可切除的非小细胞肺癌

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：新辅助放化疗可延长局部晚期食管鳞状细胞癌患者的生存期

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：ANG1005可通过血脑屏障，治疗脑转移瘤

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：伊匹单抗治疗黑色素瘤，效果如何？（EORTC 18071试验）

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：Alisertib治疗神经内分泌前列腺癌

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）

2016-10-11

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2016ESMO临床诊疗指南——胃癌的诊断、治疗与随访发布

2016-10-02

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2016ESMO临床诊疗指南——胆管癌的诊断、治疗与随访发布

2016-09-30

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2016ESMO临床实践指南——转移性非小细胞肺癌的诊断、治疗和随访发布

2016-09-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2016MASCC/ESMO指南——放化疗相关性恶心呕吐以及晚期肿瘤患者恶心呕吐的预防发布

2016-09-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2016ESMO临床实践指南——发热性中性粒细胞减少的管理发布

2016-09-29

科室
- - 订阅+
  - 更多科室
工具
服务